{
    "clinical_study": {
        "@rank": "134543", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A1: Lu AE58054 or placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort A2: Lu AE58054 or placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort B1: Lu AE58054", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and tolerability of single- and multiple doses of Lu AE58054 in\n      healthy young Japanese men in comparison with Caucasian men."
        }, 
        "brief_title": "Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects", 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "The study will be conducted in two parts.\n\n      Part A consists of two cohorts (named cohort A1 and A2), which are randomised, double-blind,\n      parallel-group, placebo-controlled, single- and multiple dose regimens investigating the\n      safety, tolerability, and pharmacokinetics of Lu AE58054 in healthy young men.\n\n      Part B consists of one cohort, B1, which is a randomised, open-label, two-way cross-over,\n      single dose investigation of the effect of food on the pharmacokinetics of Lu AE58054 in\n      healthy young Japanese men."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Japanese (Japanese passport, four Japanese grandparents, and lives outside\n             Japan for less than 5 years) or Caucasian men aged 20 to 45 years with a BMI between\n             18 and 25 kg/m2 (extremes included).\n\n        Exclusion Criteria:\n\n          -  The subject is, in the opinion of the investigator, unlikely to comply with the\n             clinical study protocol or is unsuitable for any other reason.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975779", 
            "org_study_id": "14917A", 
            "secondary_id": "2012-005648-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort A1: Lu AE58054 or placebo", 
                "description": "One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.", 
                "intervention_name": "Cohort A1: Lu AE58054 or placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort A2: Lu AE58054 or placebo", 
                "description": "One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.", 
                "intervention_name": "Cohort A2: Lu AE58054 or placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort B1: Lu AE58054", 
                "description": "Two single oral doses 60 mg with >=7 days washout.", 
                "intervention_name": "Cohort B1: Lu AE58054", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW10 7EW"
                }, 
                "name": "GB001"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "Interventional, Randomised, Double-blind, Placebocontrolled, Single- and Multiple-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects", 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Standard clinical safety assessments", 
                "measure": "Number and frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 13"
            }, 
            {
                "description": "Adverse event monitoring", 
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 13"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975779"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the Lu AE58054 plasma concentration-time curve in a dosing interval (AUC0-tau)", 
                "safety_issue": "No", 
                "time_frame": "Day 9"
            }, 
            {
                "measure": "Area under the Lu AE58054 plasma concentration-time curve from zero to infinity (AUC0-inf)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Maximum observed concentration (Cmax) and time of observation (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 9"
            }, 
            {
                "measure": "Oral clearance (CL/F), apparent volume of distribution (Vz/F), and elimination halflife (t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 9"
            }, 
            {
                "measure": "Accumulation index following multiple dosing of Lu AE58054 (AI)", 
                "safety_issue": "No", 
                "time_frame": "Day 9"
            }, 
            {
                "description": "Columbia Suicide Severity Rating Scale (C-SSRS) categorisation based on Columbian Classification Algorithm for Suicide Assessment (C-CASA) definitions for Part A", 
                "measure": "Risk of Suicidality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 13"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}